Regenxbio Inc. (RGNX) Given a $25.00 Price Target by Piper Jaffray Cos. Analysts
Regenxbio Inc. (NASDAQ:RGNX) has been given a $25.00 price objective by equities research analysts at Piper Jaffray Cos. in a report released on Monday. The firm presently has a a “buy” rating on the stock. Piper Jaffray Cos.’s target price suggests a potential upside of 40.29% from the company’s previous close.
Several other equities analysts have also recently issued reports on the company. Zacks Investment Research raised Regenxbio from a “sell” rating to a “hold” rating in a research note on Friday, August 26th. Chardan Capital reissued a “buy” rating on shares of Regenxbio in a research note on Monday, August 22nd. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Regenxbio has a consensus rating of “Buy” and a consensus target price of $26.75.
Shares of Regenxbio (NASDAQ:RGNX) traded down 0.79% during midday trading on Monday, hitting $17.68. The stock had a trading volume of 211,916 shares. The stock’s market cap is $467.90 million. The stock’s 50-day moving average is $13.90 and its 200-day moving average is $11.22. Regenxbio has a 12 month low of $7.07 and a 12 month high of $25.00.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/regenxbio-inc-rgnx-given-a-25-00-price-target-by-piper-jaffray-cos-analysts.html
Regenxbio (NASDAQ:RGNX) last posted its earnings results on Tuesday, August 9th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by $0.02. Regenxbio had a negative net margin of 451.73% and a negative return on equity of 17.89%. Equities analysts anticipate that Regenxbio will post ($2.37) EPS for the current year.
A number of large investors have recently modified their holdings of RGNX. Nationwide Fund Advisors boosted its stake in shares of Regenxbio by 196.1% in the second quarter. Nationwide Fund Advisors now owns 12,815 shares of the company’s stock valued at $103,000 after buying an additional 8,487 shares during the last quarter. Metropolitan Life Insurance Co. NY bought a new stake in Regenxbio during the second quarter valued at approximately $136,000. Rhumbline Advisers bought a new stake in Regenxbio during the second quarter valued at approximately $148,000. A.R.T. Advisors LLC bought a new stake in Regenxbio during the second quarter valued at approximately $220,000. Finally, Strs Ohio increased its stake in Regenxbio by 19.6% in the second quarter. Strs Ohio now owns 29,600 shares of the company’s stock valued at $236,000 after buying an additional 4,859 shares during the period. 68.73% of the stock is currently owned by institutional investors.
Regenxbio Company Profile
REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).
Receive News & Ratings for Regenxbio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.